Context Therapeutics (NASDAQ:CNTX) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Context Therapeutics (NASDAQ:CNTX) from a sell rating to a strong sell rating in a report published on Monday.

CNTX has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. Maxim Group dropped their target price on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th. D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Tuesday, March 24th. Guggenheim reissued a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a report on Tuesday, March 24th. Finally, Piper Sandler lifted their price objective on Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $6.17.

Context Therapeutics Trading Up 2.7%

Shares of CNTX opened at $0.62 on Monday. The company has a market cap of $56.60 million, a price-to-earnings ratio of -1.47 and a beta of 1.75. The business’s fifty day simple moving average is $1.39 and its two-hundred day simple moving average is $2.01. Context Therapeutics has a 12 month low of $0.55 and a 12 month high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.03. As a group, research analysts forecast that Context Therapeutics will post -0.39 EPS for the current year.

Institutional Investors Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Context Therapeutics by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the period. Citadel Advisors LLC purchased a new stake in Context Therapeutics in the 3rd quarter worth approximately $100,000. Blue Owl Capital Holdings LP increased its stake in shares of Context Therapeutics by 0.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock worth $10,926,000 after purchasing an additional 25,000 shares in the last quarter. Renaissance Technologies LLC increased its stake in Context Therapeutics by 58.8% in the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after buying an additional 188,202 shares in the last quarter. Finally, State Street Corp raised its stake in Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after purchasing an additional 13,000 shares during the period. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.